Mental Illness Drugs Market Trends, Size, Competitive Analysis and Forecast 2021-2027

The global mental illness drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market include the rise in the prevalence of mental health disorders, such as schizophrenia and bipolar disorder among the population. According to the Anxiety and Depression Association of America, Anxiety disorders are the most common mental illness in the US, affecting 40 million adults in the US aged 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder. The World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. Moreover, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, globally.

To Request a Sample of our Report on Mental Illness Drugs Market: https://www.omrglobal.com/request-sample/mental-illness-drugs-market

Anxiety disorders are the most common psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience the ill effects of uneasiness. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, the rising prevalence of mental disorders is contributing to the growth of the market. Schizophrenia is a serious mental disorder and is affecting a large number of people across the globe. The disease is mainly characterized by distortions in thinking, emotions, and sense of self and behavior. World Health Organization has stated that around 23 million people across the globe are affected by this disorder among which 12 million are male and 9 million are females. National Institute of Mental Health has stated that the prevalence of Schizophrenia and related symptoms is around 0.25% and 0.64% and this is increasing rapidly. This rise in the prevalence of the disease is contributing to market growth during the forecast period.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Product Type

· By Application

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

· Competitive Landscape: Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, and Pfizer Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Mental Illness Drugs Market is Available @ https://www.omrglobal.com/industry-reports/mental-illness-drugs-market

Global Mental Illness Drugs Market Report by Segment

By Product Type

· Antipsychotics

· Antidepressants

· Anxiolytics

· Anti-Seizure

· Stimulants

By Application

• Hospitals

• Clinics

• Drug Stores

Global Mental Illness Drugs Market by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.